continu infus alpha interferon advanc cancer report initi treatment result twenty-four patient advanc metastat cancer continu intraven infus interferon unit time week averag durat treatment day day plan time treatment patient averag interferon inject object tumor respons untreat patient twenty-two patient toxic equal ecog II treatment interrupt subsequ dose reduct follow reason mucos hand-foot syndrom leukopenia incid treatment toxic infus true augment effect interferon infus alpha interferon use combin evalu futur phase II phase iii trial 